Biohaven Antibody Therapy Enhancer Neutralizes Multiple Strains Of COVID-19

 -Biohaven's proprietary MATE™ conjugation platform has been used to generate a new class of antibody-based therapies to target COVID-19

-BHV-1200, a COVID-19 targeting MATE compound, recently completed in vitro testing that demonstrated activity against SARS-CoV-2 wild-type as well as mutants associated with reduced susceptibility to therapeutic monoclonal antibodies and emerging strains including the "English" and "South African" variants

-Based upon the in vitro profile against SARS-CoV-2 wild-type and variants, Biohaven will advance BHV-1200 into the clinic

https://www.prnewswire.com/news-releases/biohavens-bhv-1200-a-multimodal-antibody-therapy-enhancer-mate-demonstrates-effective-neutralization-of-multiple-strains-of-covid-19-301232221.html